The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
ecancermedicalscience
Open accessAbstract
The Fourth Metronomic and Anti-angiogenic Therapy Meeting was held in Milan 24-25 June 2014. The meeting was a true translational meeting where researchers and clinicians shared their results, experiences, and insights in order to continue gathering useful evidence on metronomic approaches. Several speakers emphasised that exact mechanisms of action, best timing, and optimal dosage are still not well understood and that the field would learn a lot from ancillary studies performed during the clinical trials of metronomic chemotherapies. From the pre-clinical side, new research findings indicate additional possible mechanisms of actions of metronomic schedule on the immune and blood vessel compartments of the tumour micro-environment. New clinical results of metronomic chemotherapy were presented in particular in paediatric cancers [especially neuroblastoma and central nervous system (CNS) tumours], in angiosarcoma (together with beta-blockers), in hepatocellular carcinoma, in prostate cancer, and in breast cancer. The use of repurposed drugs such as metformin, celecoxib, or valproic acid in the metronomic regimen was reported and highlighted the potential of other candidate drugs to be repurposed. The clinical experiences from low- and middle-income countries with affordable regimens gave very encouraging results which will allow more patients to be effectively treated in economies where new drugs are not accessible. Looking at the impact of metronomic approaches that have been shown to be effective, it was admitted that those approaches were rarely used in clinical practice, in part because of the absence of commercial interest for companies. However, performing well-designed clinical trials of metronomic and repurposing approaches demonstrating substantial improvement, especially in populations with the greatest unmet needs, may be an easier solution than addressing the financial issue. Metronomics should always be seen as a chance to come up with new innovative affordable approaches and not as a cheap rescue strategy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Browder, T. D., Butterfield, C., Kräling, B. M., Shi, B., Marshall, B., OʼReilly, M., & Folkman, J. (2000) · PubMed · Cited by 1,543
Klement, G., Baruchel, S., Rak, J., Man, S., Clark, K., Hicklin, D. J., Bohlen, P., & Kerbel, R. S. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8829 · Cited by 1,168
Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice
Hanahan, D., Bergers, G., & Bergsland, E. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9872 · Cited by 865
Adjuvant Mitotane Treatment for Adrenocortical Carcinoma
Terzolo, M., Angeli, A., Fassnacht, M., Daffara, F., Tauchmanova, L., Conton, P. A., Rossetto, R., Buci, L., Sperone, P., Grossrubatscher, E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa063360 · Cited by 764
Metronomic chemotherapy: new rationale for new directions
Pasquier, E., Kavallaris, M., & André, N. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.82 · Cited by 659
Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors
Shaked, Y., Ciarrocchi, A., Franco, M., Lee, C. R., Man, S., Cheung, A. M., Hicklin, D. J., Chaplin, D., Foster, F. S., Benezra, R., et al. (2006) · Science · doi:10.1126/science.1127592 · Cited by 570
Pietras, K., & Hanahan, D. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.093 · Cited by 479
Bertolini, F., Paul, S., Mancuso, P., Monestiroli, S., Gobbi, A., Shaked, Y., & Kerbel, R. S. (2003) · PubMed · Cited by 462
Metronomics: towards personalized chemotherapy?
André, N., Carré, M., & Pasquier, E. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.89 · Cited by 320
Biomarkers and surrogate end points—the challenge of statistical validation
Buyse, M., Sargent, D. J., Grothey, A., Matheson, A., & de Gramont, A. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.43 · Cited by 314
Pasquier, E., Ciccolini, J., Carre, M., Giacometti, S., Fanciullino, R., Pouchy, C., Montero, M.-P., Serdjebi, C., Kavallaris, M., & André, N. (2011) · Oncotarget · doi:10.18632/oncotarget.343 · Cited by 234
Ge, Y., Domschke, C., Stoiber, N., Schott, S., Heil, J., Rom, J., Blumenstein, M., Thum, J., Sohn, C., Schneeweiss, A., et al. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1106-3 · Cited by 228
Bottini, A., Generali, D., Brizzi, M. P., Fox, S. B., Bersiga, A., Bonardi, S., Allevi, G., Aguggini, S., Bodini, G., Milani, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.5773 · Cited by 189
Has the time come for metronomics in low-income and middle-income countries?
André, N., Banavali, S., Snihur, Y., & Pasquier, E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70056-1 · Cited by 174
(2016) · ecancermedicalscience · doi:10.3332/ecancer.2014.442 · Cited by 173
Sperone, P., Ferrero, A., Daffara, F., Priola, A., Zaggia, B., Volante, M., Santini, D., Vincenzi, B., Badalamenti, G., Intrivici, C., et al. (2010) · Endocrine-Related Cancer · doi:10.1677/erc-09-0281 · Cited by 167
Repurposing Drugs in Oncology (ReDO)—itraconazole as an anti-cancer agent
Pantziarka, P. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.521 · Cited by 165
Pasquier, E., Street, J., Pouchy, C., Carre, M., Gifford, A. J., Murray, J., Norris, M. D., Trahair, T., Andre, N., & Kavallaris, M. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.205 · Cited by 162
Berruti, A., Sperone, P., Ferrero, A., Germano, A., Ardito, A., Priola, A. M., Francia, S. D., Volante, M., Daffara, F., Generali, D., et al. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0918 · Cited by 146
Shaked, Y., Emmenegger, U., Francia, G., Chen, L., Lee, C. R., Man, S., Paraghamian, A., Ben‐David, Y., & Kerbel, R. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0765 · Cited by 131
Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors
Peyrl, A., Chocholous, M., Kieran, M. W., Azizi, A. A., Prucker, C., Czech, T., Dieckmann, K. U., Schmook, M. T., Haberler, C., Leiss, U., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.24006 · Cited by 124
Orlando, L., Cardillo, A., Ghisini, R., Rocca, A., Balduzzi, A., Torrisi, R., Peruzzotti, G., Goldhirsch, A., Pietri, E., & Colleoni, M. A. (2006) · BMC Cancer · doi:10.1186/1471-2407-6-225 · Cited by 119
From tumor cell metabolism to tumor immune escape
Villalba, M., Rathore, M. G., López-Royuela, N., Krzywińska, E., Garaude, J., & Allende-Vega, N. (2012) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2012.04.024 · Cited by 119
The adhesion molecule L1 regulates transendothelial migration and trafficking of dendritic cells
Maddaluno, L., Verbrugge, S. E., Martinoli, C., Matteoli, G., Chiavelli, A., Zeng, Y., Williams, E. D., Rescigno, M., & Cavallaro, U. (2009) · The Journal of Experimental Medicine · doi:10.1084/jem.20081211 · Cited by 99
Watanabe, T., Sano, M., Takashima, S., Kitaya, T., Tokuda, Y., Yoshimoto, M., Kohno, N., Nakagami, K., Iwata, H., Shimozuma, K., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.3939 · Cited by 92
Optimal and suboptimal protocols for a class of mathematical models of tumor anti-angiogenesis
Ledzewicz, U., & Schättler, H. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.02.014 · Cited by 92
Stempak, D., Gammon, J., Halton, J., et al. (2006) · Journal of Pediatric Hematology/Oncology · doi:10.1097/01.mph.0000243657.64056.c3 · Cited by 88
Fontana, A., Galli, L., Fioravanti, A., Orlandi, P., Galli, C., Landi, L. M., Bursi, S., Allegrini, G., Fontana, E., Marsico, R. D., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3317 · Cited by 88
Berruti, A., Fazio, N., Ferrero, A., Brizzi, M. P., Volante, M., Nobili, E., Tozzi, L., Bodei, L., TORTA, M., D’Avolio, A., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-184 · Cited by 88
Zapletalová, D., André, N., Deak, L., Kýr, M., Bajčiová, V., Múdrý, P., Dubská, L. Z., Demlová, R., Pavelka, Z., Zitterbart, K., et al. (2012) · Oncology · doi:10.1159/000336483 · Cited by 86
Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma
Wolter, J. K., Wolter, N. E., Blanch, A., Partridge, T., Cheng, L. S., Morgenstern, D. A., Podkowa, M., Kaplan, D. R., & Irwin, M. S. (2013) · Oncotarget · doi:10.18632/oncotarget.1083 · Cited by 80
Štěrba, J., Valík, D., Múdry, P., Kepák, T., Pavelka, Z., Bajčiová, V., Zitterbart, K., Kadlecová, V., & Mazánek, P. (2006) · Oncology Research and Treatment · doi:10.1159/000093474 · Cited by 78
Metronomic Capecitabine in Advanced Hepatocellular Carcinoma Patients: A Phase II Study
Brandi, G., Rosa, F. D., Agostini, V., Girolamo, S. D., Andreoné, P., Bolondi, L., Serra, C., Sama, C., Golfieri, R., Gramenzi, A., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2013-0093 · Cited by 72
Allegrini, G., Desidero, T. D., Barletta, M. T., Fioravanti, A., Orlandi, P., Canu, B., Chericoni, S., Loupakis, F., Paolo, A. D., Masi, G., et al. (2012) · Angiogenesis · doi:10.1007/s10456-012-9260-6 · Cited by 70
Allegrini, G., Falcone, A., Fioravanti, A., Barletta, M. T., Orlandi, P., Loupakis, F., Cerri, E., Masi, G., Paolo, A. D., Kerbel, R. S., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604311 · Cited by 67
Hasnis, E., Alishekevitz, D., Gingis‐Velitski, S., Bril, R., Fremder, E., Voloshin, T., Raviv, Z., Karban, A. A., & Shaked, Y. (2014) · Neoplasia · doi:10.1016/j.neo.2014.05.011 · Cited by 67
Brizzi, M. P., Berruti, A., Ferrero, A., Milanesi, E., Volante, M., Castiglione, F., Birocco, N., Bombaci, S., Perroni, D., Ferretti, B., et al. (2009) · BMC Cancer · doi:10.1186/1471-2407-9-388 · Cited by 64
Pai, P., Vaidya, A. W., Prabhash, K., et al. (2013) · Indian Journal of Cancer · doi:10.4103/0019-509x.117024 · Cited by 56
Perroud, H. A., Rico, M. J., Alasino, C. M., Queralt, F., Mainetti, L. E., Pezzotto, S. M., Rozados, V. R., & Scharovsky, O. G. (2013) · Future Oncology · doi:10.2217/fon.12.196 · Cited by 50
Masuda, N., Higaki, K., Takano, T., Matsunami, N., Morimoto, T., Ohtani, S., Mizutani, M., Miyamoto, T., Kuroi, K., Ohno, S., et al. (2014) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-014-2492-y · Cited by 39
Biological targeted therapies in patients with advanced enteropancreatic neuroendocrine carcinomas
Fazio, N., Cinieri, S., Lorizzo, K., Squadroni, M., Orlando, L., Spada, F., Maiello, E., Bodei, L., Paganelli, G., Fave, G. D., et al. (2010) · Cancer Treatment Reviews · doi:10.1016/s0305-7372(10)70026-8 · Cited by 36
Chemical Metabolic Inhibitors for the Treatment of Blood-Borne Cancers
Villalba, M., López-Royuela, N., Krzywińska, E., Rathore, M. G., Hipskind, R. A., Haouas, H., & Allende-Vega, N. (2014) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/18715206113136660374 · Cited by 32
Metronomic chemotherapy in advanced oral cancers
Prabhash, K., Patil, V., Noronha, V., Dcruz, A. K., & Banavali, S. D. (2012) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.92223 · Cited by 31
Mercurio, S., Padovani, L., Colin, C., Carré, M., Tchoghandjian, A., Scavarda, D., Lambert, S. R., Baeza, N., Fernandez, C., Chappé, C., et al. (2013) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-1-17 · Cited by 19
Antiangiogenic effect of propranolol on the growth of the neuroblastoma xenografts in nude mice
Xu, T., Xiao, X., Zheng, S., Zheng, J., Zhu, H., Ji, Y., & Yang, S. (2013) · Journal of Pediatric Surgery · doi:10.1016/j.jpedsurg.2013.08.022 · Cited by 15
Rico, M. J., Perroud, H. A., Mainetti, L. E., Rozados, V. R., & Scharovsky, O. G. (2014) · Cancer Investigation · doi:10.3109/07357907.2013.877480 · Cited by 6
Cited by
Geographic influences in the global rise of thyroid cancer
Kim, J., Gosnell, J. E., & Roman, S. A. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0263-x · Cited by 473
Collaborative, W. I. F. T. P. H. I. A. T. –. A. H. I. D., Mutale, W., Chintu, N., Amoroso, C., Awoonor-Williams, K., Phillips, J., Baynes, C., Michel, C., Taylor, A., & Sherr, K. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-s2-s9 · Cited by 341
Exploiting evolutionary principles to prolong tumor control in preclinical models of breast cancer
Enriquez-Navas, P. M., Kam, Y., Das, T., Hassan, S., Silva, A., Foroutan, P., Ruiz, E., Martinez, G., Minton, S., Gillies, R. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7842 · Cited by 322
Micelles with ultralow critical micelle concentration as carriers for drug delivery
Lu, Y., Yue, Z., Xie, J., Wang, W., Zhu, H., Zhang, E., & Cao, Z. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0234-x · Cited by 313
Current approaches to the treatment of metastatic brain tumours
Owonikoko, T. K., Arbiser, J., Zelnak, A., Shu, H.-K. G., Shim, H., Robin, A. M., Kalkanis, S. N., Whitsett, T. G., Salhia, B., Tran, N. L., et al. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.25 · Cited by 304
Metadata
- Venue
- ecancermedicalscience
- Publisher
- Ecancer Global Foundation
- Published
- 2016-12-08
- Volume
- 8
- Pages
- 463-463
- ISSN
- 1754-6605 (ISSN-L)
- OpenAlex
- W2124343455
- Cited by
- 676
- References
- 46
- Type
- paratext
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.